RC June

Debate: BTK Inhibitors vs Bendamustine-Rituximab (BR) as Primary Therapy - DISCUSSION

Moderator(s)

• 

  Jordan D. Berlin, MD

  Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
  Nashville, Tennessee

Panelist(s)

• 

  Prashant Kapoor, MD

  Mayo Clinic
  Rochester, Minnesota
• 

  Jeffrey Matous, MD

  CBCI- Colorado Blood Cancer Institute
  Denver, Colorado